Clinical Trial Update: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events [Phase 3]

View source ↗

Summary

Phase 3 randomized trial of bococizumab in people with primary hyperlipidemia or mixed dyslipidemia at risk for cardiovascular events completed; results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hyperlipidemia

Drugs mentioned

• Bococizumab (bococizumab)

Snippet

Sponsor: Pfizer | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED | Results posted: 2017-07-21